Supreme Court’s Mifepristone Ruling: Could Abortion Pills by Mail Be Banned Nationwide?

The Supreme Court has extended its temporary pause on a restrictive Fifth Circuit ruling, ensuring that access to the abortion pill mifepristone by mail and through telehealth remains available nationwide for at least three more days. The decision, announced on May 13, 2026, follows a legal battle between Louisiana and drug manufacturers over the drug’s distribution methods, with Justice Samuel Alito extending the administrative stay until at least 5 p.m. EDT on Thursday, May 14.

The dispute centers on Louisiana’s lawsuit against the FDA, which seeks to eliminate telehealth and mail-order access to mifepristone—a drug used in medication abortions, which account for the majority of abortions in the U.S. The Fifth Circuit Court of Appeals initially sided with Louisiana in early May, temporarily blocking nationwide telehealth and mail-order access. However, the Supreme Court intervened, temporarily restoring access while it considers the broader implications of the case.

Louisiana argues that telehealth and mail-order access to mifepristone enable patients to bypass state abortion bans, claiming this constitutes a “sovereign injury” to the state. The state contends that federal policies allowing remote prescriptions and mail-order shipments undermine its ability to enforce its own laws. In contrast, the two manufacturers of mifepristone—Danco Laboratories and GenBioPro—argue that Louisiana lacks standing to challenge the FDA’s policies and that the current rules have been in place for years without evidence of harm.

The Supreme Court’s decision to extend the stay reflects ongoing uncertainty over how the justices will rule on the case’s merits. While the Court has previously ruled in favor of the FDA’s authority over mifepristone (e.g., in FDA v. Alliance for Hippocratic Medicine in 2024), this case tests whether states can override federal policies to restrict access. Legal experts suggest the Court may avoid a direct ruling on abortion rights, instead focusing on procedural questions like standing or federal preemption.

If the Court ultimately sides with Louisiana, access to mifepristone by mail and telehealth could be severely limited, forcing patients in states with abortion bans to seek in-person care—a challenge given the shortage of providers in many regions. Some abortion providers have already prepared contingency plans, such as shifting to misoprostol-only regimens, which do not require mifepristone. However, such workarounds may not be as reliable or accessible as the two-drug protocol.

The stakes are particularly high given that medication abortion has become the predominant method for terminating pregnancies in the U.S., especially since the overturning of Roe v. Wade in 2022. Over a quarter of medication abortions now occur via telehealth, a trend that has expanded access in states with restrictive laws. Restricting telehealth access would disproportionately affect rural and low-income patients, who often rely on remote care due to limited local resources.

The Trump administration has remained silent on the issue, despite its previous support for FDA authority in lower courts. The FDA itself is reviewing the safety of mifepristone but has not yet weighed in on the Supreme Court’s deliberations. The absence of a federal response leaves the outcome largely in the hands of the justices, who may seek to avoid a sweeping ruling on abortion rights while addressing the immediate conflict between state and federal authority.

As the Court’s stay nears its expiration on May 14, the legal and political ramifications of this case will continue to unfold. For now, patients nationwide can still access mifepristone by mail and telehealth, but the future of these policies remains uncertain.